Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 13/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12398156 | 0.94 | VDR (0.48) | VDRMEN1NR1I2PGRKMT2A | |
| SCHEMBL17340174 | 0.92 | VDR (0.55) | VDRMEN1NR1I2PGRKMT2A | |
| SCHEMBL12398151 | 0.88 | VDR (0.45) | VDR | |
| SCHEMBL12398307 | 0.88 | VDR (0.56) | VDRMEN1NR1I2PGRKMT2A | |
| SCHEMBL14489015 | 0.86 | VDR (0.46) | VDRMEN1NR1I2PGRKMT2A | |
| SCHEMBL12398187 | 0.86 | VDR (0.48) | VDRMEN1NR1I2PGRKMT2A | |
| SCHEMBL12398139 | 0.86 | VDR (0.53) | VDR | |
| SCHEMBL12397902 | 0.85 | VDR (0.61) | VDRMEN1NR1I2PGRKMT2A | |
| SCHEMBL12047755 | 0.85 | VDR (0.61) | VDRMEN1NR1I2PGRKMT2A | |
| SCHEMBL3184514 | 0.84 | VDR (0.52) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212136-B2 | Methods for producing paricalcitol | AZAD PHARMACEUTICALS INGREDIENTS AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20110184199-A1 | Methods For Producing Paricalcitol | AZAD PHARMA AG (CH) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184199-A1 | Methods For Producing Paricalcitol | CYP2R1, PTH1R, CYP24A1 | VDR 18/4885MEN1 387/4885NR1I2 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.